Table 3

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*

, Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Incremental cost-effectiveness ratios of alternative HPV vaccination strategies with varying start age of vaccination*

Strategy	Discounted total		Incremental
Strategy	Costs	QALY	$/QALY†
18-y-old women plus 18- to 24-y-old female catch-up	73,553,847	2,699,192	1,858
15-y-old female adolescents plus 15- to 24-y-old female catch-up	73,895,046	2,699,214	Weakly dominated
12-y-old girls plus 12- to 24-y-old female catch-up	74,815,667	2,699,343	8,357
18-y-old women and men plus 18- to 24-y-old female and male catch-up	77,535,383	2,699,385	Weakly dominated
15-y-old female and male adolescents plus 15- to 24-y-old female and male catch-up	78,455,750	2,699,404	Weakly dominated
12-y-old female and male adolescents plus 12- to 24-y-old female and male catch-up program	81,761,210	2,699,506	42,697

*Assumes cost of vaccination series is US $360, duration of protection is lifelong, and coverage rate of 50% among age 15- to 24-y-olds. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A. A strategy is weakly dominated if there is another more effective program that has a incremental cost-effectiveness ratio.

Main Article

Page created: June 28, 2010

Page updated: June 28, 2010

Page reviewed: June 28, 2010

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.